Cancer Chemother Pharmacol
Aniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsBenzamides
Dr. Anna Flora Farago, MD, PhD
NPI1114185527
- Medicare services, 2020
- 248
- Part D claims, 2020
- 54
- Publications
- 53
- Clinical trials
- 7
- Industry payments
- $144,455
- Practice address
- 25 Highland Ave, Newburyport, MA 01950
- Practice phone
- Call (617) 724-4000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Farago's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Anna Flora Farago is a hematologist and oncologist in Newburyport, Massachusetts
Dr. Farago practices in Newburyport, Massachusetts.
Dr. Farago's NPI, 1114185527, was assigned on June 2, 2008. Dr. Farago holds Massachusetts license 242962.
NPI and contact details
- NPI
- 1114185527NPI Registry (opens in a new tab)
- NPI enumeration date
- June 2, 2008
- NPI status
- Active
- Practice phone
- (617) 724-4000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. Anna Flora Farago's practice address is in Newburyport, Massachusetts
Dr. Farago's practice address in the NPI Registry is 25 Highland Ave, Newburyport, MA 01950, in Essex County. The practice phone is (617) 724-4000.
- NPI Registry address25 Highland Ave, Newburyport, MA 01950 · Essex CountyPhone(617) 724-4000
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. Anna Flora Farago's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Farago practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Farago's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Farago practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Anna Flora Farago is one of 429 hematologists and oncologists in Massachusetts
Hematology and oncology is Dr. Farago's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Farago is licensed in Massachusetts.
Specialties and state licenses
- Hematology and oncology, MassachusettsPrimary
Hematologists and oncologists near Dr. Farago
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Anna Flora Farago billed Medicare for 248 services in 2020
CMS data shows 248 Medicare services from Dr. Farago across 5 procedure codes in 2020. Medicare paid $18,178 for them.
Medicare services, 2020248
Paid by Medicare$18,178
Procedure codes5
Dr. Farago's Medicare services by type, 2019 to 2020
- 2019
- 2020
- Office and hospital visits
- 2019: 3982020: 24838%
Where Dr. Farago's Medicare services took place, 2020
- In an office5623%
- In a facility19277%
Dr. Farago compared with the Massachusetts median for hematologists and oncologists, 2020
- Dr. Farago
- Massachusetts median
- Medicare services
- 248vs 49550% below
- Part D claims
- 54vs 15164% below
Medians across 415 hematologists and oncologists in Massachusetts with Dmand AI profiles that report each measure.
Dr. Farago's most billed Medicare procedure codes, 2020
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Farago?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Farago and other hematologists and oncologists in Massachusetts.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Anna Flora Farago's patients have a median age of 79
Across all payers, Dmand AI patient panel data puts Dr. Farago's median patient age at 79, with 0% women.
Dr. Farago's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 79
Patient panel by sex, all payers
- Women0%
- Men100%
Source: Dmand AI Patient Panel Data
Dr. Anna Flora Farago wrote 54 Medicare Part D claims in 2020
In 2020, Dr. Farago wrote 54 Medicare Part D claims. They cover 3 drugs, with $454,226 in total drug cost. In 2019, CMS named 117 claims across 7 drugs.
Part D claims, 202054
Drugs named by CMS3
Total drug cost$454,226
Dr. Farago's most prescribed drugs by claims, 2020
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2019 to 2020
- 2019
- 2020
- Claims for drugs CMS names
- 2019: 1172020: 5454%
Drugs named by CMS: 3 in 2020, 7 in 2019.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Farago by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Anna Flora Farago has 53 publications on record
Dmand AI links 53 papers to Dr. Farago, published from 2013 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Lung Neoplasms, Small Cell Lung Carcinoma and Protein Kinase Inhibitors. Dr. Farago has published most often in Cancer Discov. Dr. Farago's most frequent co-authors are Zofia Piotrowska, MD, Lecia V. Sequist, MD and Benjamin J. Drapkin, MD, PhD.
Papers53
Years published2013 to 2025
Dr. Farago's papers by year, 2016 to 2025
Topics Dr. Farago writes about most
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Protein Kinase Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Pyrazoles
- Benzamides
- Biomarkers, Tumor
Dr. Farago's most frequent co-authors
- Zofia Piotrowska, MD11 shared papers
- Lecia V. Sequist, MD11 shared papers
- Benjamin J. Drapkin, MD, PhD10 shared papers
Recent publications by Dr. Farago
Carcinoma, Non-Small-Cell LungClinical Trials, Phase II as TopicLung Neoplasms
Antineoplastic Combined Chemotherapy ProtocolsDoxorubicinLung Neoplasms
Cell Line, TumorDNADNA Damage
See who Dr. Farago researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Farago works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Anna Flora Farago has worked on 7 clinical trials
Dmand AI links Dr. Farago to 7 clinical trials, 3 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Small Cell Lung Carcinoma, Carcinoma, Bronchogenic and Carcinoma, Medullary. AbbVie sponsors the most, 2.
Clinical trials with Dr. Farago by phase
- NonePhase 1: no trials
- 3Phase 1/2: 3 trials
- 2Phase 2: 2 trials
- 1Phase 3: 1 trial
- NonePhase 4: no trials
Conditions in Dr. Farago's trials
- Small Cell Lung Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Medullary
- Thyroid Cancer, Papillary
- Adenocarcinoma, Papillary
Investigators on the most trials with Dr. Farago
- Deepa Rangachari, MD3 shared trials
- Jiaxin Niu, MD2 shared trials
- Charles M. Rudin, MD, PhD2 shared trials
Recent clinical trials with Dr. Farago
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors (opens in a new tab)
TerminatedPhase 1/2
Small Cell Lung CarcinomaNeoplasm MetastasisNavitoclaxVistusertib
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy (opens in a new tab)
Status unknownPhase 1/2
Small Cell Lung CarcinomaCarcinoma, BronchogenicOlaparibTemozolomide
Small Cell Lung CarcinomaCarcinoma, BronchogenicLurbinectedin (PM01183)TopotecanCyclophosphamide (CTX)
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors (opens in a new tab)
TerminatedPhase 1/2
Carcinoma, MedullaryCarcinoma, NeuroendocrineRovalpituzumab tesirineDexamethasone
Small Cell Lung CarcinomaCarcinoma, BronchogenicRovalpituzumab tesirine
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Anna Flora Farago received $144,455 in industry payments from 2016 to 2020
CMS Open Payments shows 174 general payments to Dr. Farago from 9 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 76% of the total. AstraZeneca Pharmaceuticals LP paid the most, $39,442. It also lists 21 research payments totaling $10,006 from 2016 to 2021.
General payments to Dr. Farago by program year, 2016 to 2020
General payments to Dr. Farago by kind, 2016 to 2020
$144.5Kin total
- Consulting fees$109,37676%
- Travel and lodging$25,85018%
- Speaker and faculty fees$5,3634%
- Food and beverage$3,8663%
Companies that paid Dr. Farago the most, 2016 to 2020
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Anna Flora Farago's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Anna Flora Farago
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Anna Flora Farago's NPI number?
Dr. Anna Flora Farago's NPI number is 1114185527. It was assigned on June 2, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Anna Flora Farago?
Dr. Anna Flora Farago is a hematologist and oncologist in Newburyport, Massachusetts. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Anna Flora Farago practice?
Dr. Farago practices at 25 Highland Ave, Newburyport, MA 01950.
What is Dr. Anna Flora Farago's office phone number?
The practice phone on file for Dr. Farago is (617) 724-4000.
What is Dr. Anna Flora Farago's medical license number?
Dr. Farago holds Massachusetts license 242962.
Does Dr. Anna Flora Farago accept Medicare?
Yes. CMS data shows Dr. Farago billed Medicare for 248 services in 2020.
What services does Dr. Anna Flora Farago bill to Medicare?
In 2020, Dr. Farago's most billed Medicare services were office visit, established patient (99214), office visit, established patient (99215) and care management and other visits (99443).
What drugs does Dr. Anna Flora Farago prescribe most?
In 2020 Medicare Part D data, Dr. Farago's most prescribed drugs by claims were Tagrisso, Dexamethasone and Omeprazole.
Has Dr. Anna Flora Farago received payments from drug or device companies?
CMS Open Payments shows $144,455 in general payments to Dr. Farago from 9 companies from 2016 to 2020. The largest total came from AstraZeneca Pharmaceuticals LP.
How long has Dr. Anna Flora Farago been practicing?
Dr. Farago's NPI was assigned in 2008.
Does Dr. Anna Flora Farago do research?
Dmand AI links 53 publications to Dr. Farago, published from 2013 to 2025. Dr. Farago has worked on 7 clinical trials.
Who does Dr. Anna Flora Farago publish with?
Dr. Farago's most frequent co-authors are Zofia Piotrowska, MD (11 shared papers), Lecia V. Sequist, MD (11 shared papers) and Benjamin J. Drapkin, MD, PhD (10 shared papers).
Selling to hematology and oncology practices?
See hematologists and oncologists in Massachusetts by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card